In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...

The Man Who Wants to Live Forever introduced many viewers to the Minicircle company, and here's what the organization ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary ...

Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug ...